Science Explorer Interactive view Map
Company · Calgary · Canada

Resverlogix (Canada)

resverlogix.comROR OpenAlex
Research works
73
▲ 54% vs 2013–17
Citations
1.1k
14.9 per fractional work
Top-10% rate
2.8%
record average 16.5%
Open access
41%
world 28%

Not ranked overall: Resverlogix (Canada) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.89× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 6.46× its world share, 4 worksBiochemistry, Geneti…Immunology and Microbiology: 3.73× its world share, 0 worksImmunology and Micro…Chemistry: 1.05× its world share, 0 worksChemistryEngineering: 0.03× its world share, 0 worksEngineeringMathematics: 1.20× its world share, 0 worksMathematicsMedicine: 2.74× its world share, 6 worksMedicineVeterinary: 10.35× its world share, 0 worksVeterinary1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Veterinary, 10.3×. Every wedge is a field page.

Which keywords describe research at Resverlogix (Canada)?

By fractional works in all years, weighted toward what it does more of than the world: Transcriptional Regulation, BET Bromodomains, PROTACs, Cancer Therapy, Obesity, Metabolic Syndrome, Cardiovascular Disease and Inflammation.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Transcriptional Regulation20▲ 109×3 topics
  2. BET Bromodomains19▲ 1290×1 topic
  3. PROTACs19▲ 1290×1 topic
  4. Cancer Therapy7▲ 15×5 topics
  5. Inflammation6▲ 3.4×12 topics
  6. Cardiovascular Disease5▲ 6.2×11 topics
  7. Obesity5▲ 8.6×6 topics
  8. Metabolic Syndrome5▲ 7.5×6 topics
  9. Atherosclerosis4▲ 15×6 topics
  10. Heart Failure4▲ 11×4 topics
  11. Epigenetic Regulation3▲ 21×3 topics
  12. Insulin Resistance3▲ 9.8×5 topics
  13. Cancer3▲ 2.9×11 topics
  14. Proteasome Inhibitors3▲ 57×2 topics
  15. Weight Loss3▲ 25×2 topics
  16. Gene Expression3▲ 6.2×2 topics
  17. HDAC Inhibitors3▲ 189×1 topic
  18. Histone Deacetylases3▲ 189×1 topic
  19. Vaccine2▲ 8.5×2 topics
  20. Alzheimer's Disease2▲ 11×3 topics
  21. Diagnosis Criteria2▲ 98×1 topic
  22. Immune Response2▲ 4.9×7 topics
  23. International Myeloma Working Group2▲ 98×1 topic
  24. Cholesterol2▲ 16×3 topics
  25. Ketogenic Diet2▲ 27×1 topic
  26. Low-Carbohydrate Diet2▲ 32×1 topic
  27. Metabolism2▲ 4.1×7 topics
  28. ACE2 Receptor2▲ 22×2 topics
  29. SARS-CoV-22▲ 17×2 topics
  30. Clinical Guidelines2▲ 7.3×3 topics
  31. Glucose Metabolism2▲ 23×2 topics
  32. Immunity2▲ 7.0×3 topics
  33. Renal Function2▲ 20×2 topics
  34. Tumor Microenvironment2▲ 6.2×4 topics
  35. Coronary Artery Disease2▲ 17×2 topics
  36. Coronavirus2▲ 18×1 topic
  37. Hypertension2▲ 5.9×4 topics
  38. Mutation2▲ 14×2 topics
  39. spike protein2▲ 47×1 topic
  40. Endothelial Function1▲ 24×2 topics

Which research topics does Resverlogix (Canada) publish most on?

By volume in 2022–2025: Protein Degradation and Inhibitors, Heart Failure Treatment and Management, Chromatin Remodeling and Cancer and Peptidase Inhibition and Analysis.

Protein Degradation and …2Protein Degradation and Inhibitors: 2 fractional worksHeart Failure Treatment …1Heart Failure Treatment and Management: 1 fractional worksChromatin Remodeling and…1Chromatin Remodeling and Cancer: 1 fractional worksPeptidase Inhibition and Analysis: 1 fractional worksDiet, Metabolism, and Disease: 1 fractional worksRenal and Vascular Patho…0Renal and Vascular Pathologies: 0 fractional worksLiver Disease Diagnosis and Treatment: 0 fractional worksUbiquitin and proteasome pathways: 0 fractional worksCOVID-19 Clinical Research Studies: 0 fractional worksLong-Term Effects of COVID-19: 0 fractional works
Molecular BiologyCardiology and Cardiovascular MedicineOncologyEndocrinology, Diabetes and Metabolism4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Protein Degradation and InhibitorsMolecular Biology 2 works
  2. 2 Heart Failure Treatment and ManagementCardiology and Cardiovascular Medicine 1 works
  3. 3 Chromatin Remodeling and CancerMolecular Biology 1 works
  4. 4 Peptidase Inhibition and AnalysisOncology 1 works
  5. 5 Diet, Metabolism, and DiseaseEndocrinology, Diabetes and Metabolism 1 works
  6. 6 Renal and Vascular PathologiesPulmonary and Respiratory Medicine 0 works
  7. 7 Liver Disease Diagnosis and TreatmentEpidemiology 0 works
  8. 8 Ubiquitin and proteasome pathwaysMolecular Biology 0 works
  9. 9 COVID-19 Clinical Research StudiesInfectious Diseases 0 works
  10. 10 Long-Term Effects of COVID-19Neurology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available40.9%not open59.1%

World: 28% of research is openly available.

with international co-authors36.4%domestic only63.6%

World: 19% is written across borders.

How has Resverlogix (Canada)'s research output changed?

Output in 2018–2022 was 54% higher than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Calgary

All research institutions in Calgary

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.